Nov. 10 (UPI) — Brazilian officers say they’ve paused a late-phase trial for a COVID-19 vaccine being developed by China after one of many human take a look at topics died.
Anvisa, Brazil’s nationwide well being surveillance company, mentioned the “extreme opposed occasion” occurred late final month, however did not specify the circumstances of the volunteer’s loss of life.
Chinese language agency Sinovac has been performing the late-stage trial for the potential vaccine, known as CoronaVac, in collaboration with the Brazilian Butantan Institute in Sao Paulo.
“The company determined to droop the examine to judge the information noticed up to now and choose the danger and profit of continuous the examine,” Sinovac mentioned Monday.
The corporate mentioned the volunteer’s loss of life was not associated to the medical trial.
“We discovered the pinnacle of Butantan Institute believed that this severe opposed occasion is just not associated to the vaccine,” Sinovac mentioned in a press release.
“We’re assured within the security of the vaccine.”
“It is a loss of life unrelated to the vaccine as a result of there are greater than 10,000 volunteers proper now, the individual can have a visitors accident and die,” added Butantan Institute Director Dimas Covas.
“This by no means results in the interruption of a medical trial. I ask now that … these particulars get clarified.”
There are dozens of potential coronavirus vaccines presently in improvement worldwide. Pfizer mentioned Monday that early information for its final-stage candidate up to now point out that it’s about 90% efficient.